New shot for teen hay fever? early trial underway
NCT ID NCT07617324
First seen Jun 01, 2026 · Last updated Jun 23, 2026 · Updated 4 times
Summary
This phase 2 trial tests the safety of stapokibart injection in 15 teenagers aged 12-17 with seasonal allergic rhinitis (hay fever). Participants receive the drug alongside their usual allergy treatments. The study focuses on side effects and how the body processes the drug, not yet on how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEASONAL ALLERGIC RHINITIS (SAR) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tongren Hospital, CMU
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
stapokibart injection
What this could lead to
If it works, this could point toward a new treatment option for teenagers with seasonal allergies.
What could go wrong
This is a small, early-phase study with only 15 participants, so results may not apply to everyone. The main goal is safety, not yet proof of effectiveness.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.